Get the Stockscreener App
5.06
1.81%
0.09
After Hours:
5.06
Monte Rosa Therapeutics Inc stock is traded at $5.06, with a volume of 484.11K.
It is up +1.81% in the last 24 hours and up +1.00% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$4.97
Open:
$4.98
24h Volume:
484.11K
Relative Volume:
0.75
Market Cap:
$312.47M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-2.2589
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
+9.76%
1M Performance:
+1.00%
6M Performance:
-15.53%
1Y Performance:
+30.08%
1-Day Range:
$4.94
$5.13
1-Week Range:
$4.585
$5.13
52-Week Range:
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
5.06 | 312.47M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.36 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.75 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.50 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
538.64 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.47 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Monte Rosa gets FDA clearance to begin testing MRT-8102 - MSN
FMR LLC Reduces Stake in Monte Rosa Therapeutics Inc. - GuruFocus
Bank of America Corp DE Reduces Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa’s molecular glue degrader MRT-8102 gains IND clearance for inflammatory conditions - BioWorld MedTech
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Boosted by Millennium Management LLC - Defense World
Monte Rosa advances novel inflammatory disease treatment By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Says US FDA Accepts Investigational New Drug Application for MRT-8102 - marketscreener.com
Monte Rosa Therapeutics, Inc. Announces FDA Clearance of IND Application for MRT-8102, A NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - MarketScreener
Monte Rosa Therapeutics (GLUE) Gains as FDA Clears New Drug Tria - GuruFocus
Monte Rosa gets FDA clearance to begin testing MRT-8102 (GLUE) - Seeking Alpha
Monte Rosa Therapeutics (GLUE) Gains FDA Approval for MRT-8102 I - GuruFocus
Monte Rosa advances novel inflammatory disease treatment - Investing.com
Monte Rosa Therapeutics Announces FDA Clearance Of Ind Application For Mrt-8102 - MarketScreener
Monte Rosa Therapeutics Announces FDA Clearance of IND - GlobeNewswire
FDA Clearance: Monte Rosa's Revolutionary NEK7 Drug Could Transform Inflammatory Disease Treatment - Stock Titan
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet - sharewise
Two Sigma Advisers LP Takes $180,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Sold by Jane Street Group LLC - Defense World
Squarepoint Ops LLC Takes Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
6,231 Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Acquired by BNP Paribas Financial Markets - Defense World
ProShare Advisors LLC Buys New Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Deutsche Bank AG Buys 6,633 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Purchased by Two Sigma Investments LP - Defense World
CDK2 degradation inducers disclosed in Monte Rosa patent - BioWorld MedTech
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Monte Rosa CEO Reveals Latest Molecular Glue Degrader Progress at Major Healthcare Conference - Stock Titan
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) - Defense World
D. E. Shaw & Co. Inc. Raises Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Holdings Increased by Northern Trust Corp - Defense World
Revenues Working Against Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Share Price Following 26% Dive - simplywall.st
Dimensional Fund Advisors LP Has $1.01 Million Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Increased by Tower Research Capital LLC TRC - Defense World
Results: Monte Rosa Therapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st
Monte Rosa Therapeutics Inc (GLUE)’s Day in Review: Closing at 4.22, Up by 9.61 - DWinneX
Monte Rosa Therapeutics: Q1 Earnings Snapshot - New Haven Register
Barclays PLC Raises Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Reports Strong Q1 2025 Earnings - TipRanks
Monte Rosa Therapeutics Reports Strong Q1 2025 Results - MSN
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - MSN
Monte Rosa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq
Monte Rosa Therapeutics (GLUE) Advances Novel Therapeutic Progra - GuruFocus
Monte Rosa Therapeutics, Inc. SEC 10-Q Report - TradingView
Invesco Ltd. Purchases New Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monte Rosa Therapeutics Inc Stock (GLUE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leo Chandra P. | Director |
Mar 24 '25 |
Buy |
5.84 |
10,000 |
58,383 |
10,000 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 28 '24 |
Sale |
9.66 |
89,990 |
869,240 |
2,007,948 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 29 '24 |
Sale |
9.16 |
67,905 |
621,801 |
1,573,453 |
3.56%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):